# Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

> **NCT01552434** · PHASE1 · TERMINATED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 154 (actual)

## Conditions studied

- Advanced Malignant Neoplasm
- Castleman Disease
- Digestive System Carcinoma
- Erdheim-Chester Disease
- Lip and Oral Cavity Carcinoma
- Lymphangioleiomyomatosis
- Malignant Endocrine Neoplasm
- Malignant Female Reproductive System Neoplasm
- Malignant Male Reproductive System Neoplasm
- Malignant Neoplasm
- Malignant Respiratory Tract Neoplasm
- Malignant Thoracic Neoplasm
- Malignant Urinary System Neoplasm
- Mesothelial Neoplasm
- Metastatic Malignant Neoplasm
- Metastatic Urothelial Carcinoma
- Neurofibromatosis Type 2
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Breast Carcinoma
- Recurrent Childhood Soft Tissue Sarcoma
- Recurrent Digestive System Carcinoma
- Recurrent Female Reproductive System Carcinoma
- Recurrent Male Reproductive System Carcinoma
- Recurrent Malignant Neoplasm
- Recurrent Pharyngeal Carcinoma
- Recurrent Thyroid Gland Carcinoma
- Refractory Malignant Neoplasm
- Soft Tissue Neoplasm
- Stage III Breast Cancer AJCC v7
- Stage III Pharyngeal Cancer
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Stage IV Pharyngeal Cancer
- Stage IVA Pharyngeal Cancer
- Stage IVB Pharyngeal Cancer
- Stage IVC Pharyngeal Cancer
- Thyroid Gland Neoplasm

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **BIOLOGICAL:** Cetuximab
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Temsirolimus
- **DRUG:** Valproic Acid

## Key facts

- **NCT ID:** NCT01552434
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-16
- **Primary completion:** 2026-05-08
- **Final completion:** 2026-05-08
- **Target enrollment:** 154 (ACTUAL)
- **Why stopped:** \< 75 % participation
- **Last updated:** 2026-05-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01552434

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01552434, "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease". Retrieved via AI Analytics 2026-08-09 from https://api.ai-analytics.org/clinical/NCT01552434. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*